arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Sight Sciences, Inc.

SGHT
$8.51 ▼ -0.09 (-0.99%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
7 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

Sight Sciences, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $443.8M
Dividend Yield —
Revenue Growth -3.1% ↘
Op. Margin -48.0% ↗
ROIC -34.9% ↗
FCF / Share $-0.57 ↘
Trailing P/E —
Price / Book 7.1x
FCF Yield —
Debt / Equity 0.66
info Valuation on last close. End-of-day price, Sep 23, 2026.

7-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$77.36M
↓ -3.1% —
Net Income Profit after all expenses
$-38.43M
↑ +25.4% —
Operating Margin Operating profit as % of sales
-48.0%
↑ +24.2% 5th
FCF / Share Free cash flow per share
$-0.57
↓ -26.5% —
Long-Term Debt Long-term obligations
$42.38M
↑ +5.9% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
5
Returns ↓
14
Financial Health ↑
38
Cash Quality ↓
53

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 27 quarters